Business
Lantheus Reports Preliminary Fiscal Year 2023 Revenue
Full year 2023 worldwide revenue expected to be in the range of $1.295 – 1.297 billion, a 38 - 39% increase over the prior year including a $15 million
About this update from Lantheus Holdings, Inc.
[{"type":"text","content":"Full year 2023 worldwide revenue expected to be in the range of $1.295 – 1.297 billion, a 38 - 39% increase over the prior year including a $15 million RELISTOR milestone achievement Full year 2023 PYLARIFY revenue expected to be in the range of $851 - 853 million, pending final partner reconciliation, an increase of 61 - 62% over the prior year Full year 2023 DEFINITY revenue expected to be approximately $279 million, a 14% increase over the prior year BEDFORD, Mass., Jan. 09, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today reported certain preliminary unaudited financial results for its fiscal year ended December 31, 2023. Full Year 2023 Revenue Highlights Year Ended Dec. 31, 2023Year Ended Dec. 31, 2022YoY ChangeWorldwide Revenue$1.295 – 1.297 billion$935.1 million+38 - 39%PYLARIFY Revenue$851 – 853 million$527.4 million+61 - 62% “Lantheus has consistently exemplified our strong commitment to excellence and has been at the forefront in the ongoing renaissance in the radiopharmaceutical industry,” stated Mary Anne Heino, Chief Executive Officer of Lantheus. “Over the course of the past year, Lantheus has impacted the lives of more than six million patients and their families. Our efforts have resulted in record revenues and a period of exceptional achievement. As we head into 2024, Lantheus is well positioned for growth and to deliver sustained shareholder value, driven by our radiopharmaceutical platform and supported by the dedicated efforts of the Lantheus team to Find, Fight and Follow disease to deliver better patient outcomes.” Fiscal Year 2023 Revenue Worldwide revenue for the full year 2023 is expected to be in the range of $1.295 - 1.297 billion, compared with $0.935 billion for the full year 2022, which would represent an increase of approximately 38 - 39% over the prior year period, exceeding the Company’s previously issued guidance range of $1.255 - 1.270 billion;Expected worldwide revenue for the full year 2023, excluding the RELISTOR sales milestone of $15 million, represents an increase of approximately 37% over the prior year period;PYLARIFY revenue for the full year 2023 is expected to be in the range of $851 - 853 million, p...